<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71877">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170025</url>
  </required_header>
  <id_info>
    <org_study_id>17020</org_study_id>
    <secondary_id>2013-004595-35</secondary_id>
    <nct_id>NCT02170025</nct_id>
  </id_info>
  <brief_title>Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients</brief_title>
  <official_title>Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the safety, tolerability and early signs of efficacy of three times a day
      orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not
      on treatment with Orkambi
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two parts. The first part is double-blind, randomized and
      placebo-controlled. The second part has an open-label study design. In part 1 patients on
      Orkambi or other CFTR-modulators are excluded. In part 2 patients on Orkambi are allowed to
      be included under certain conditions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2014</start_date>
  <completion_date type="Anticipated">January 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of sweat chloride content from baseline</measure>
    <time_frame>Baseline, at day 14 and day 28 in study part 1 and baseline, day 14, 28, 42 and 56 in study part 2</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Arm 1: BAY63-2521</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: two dose levels (0.5 and 1 mg) of BAY63-2521 in patients without Orkambi therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: BAY63-2521</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: four dose levels (0.25, 0.5, 1 and 2 mg) of BAY63-2521 in patients without Orkambi therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: BAY63-2521</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: four dose levels (0.25, 0.5, 1 and 2 mg) of BAY63-2521 in patients with Orkambi therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY63-2521)</intervention_name>
    <description>Pat 1: The patients will receive 0.5 mg three times a day for the initial 14 days and a 1 mg for the second 14 days.</description>
    <arm_group_label>Arm 1: BAY63-2521</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Part 1: Placebo tablet, three times a day for duration of 28 days</description>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY63-2521)</intervention_name>
    <description>Part 2: Patients not on Orkambi therapy will receive 0.25 mg BAY63-2521 tid for 14 days, increasing to 0.5 mg, 1 mg and 2 mg for 14 days each.</description>
    <arm_group_label>Arm 3: BAY63-2521</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY63-2521)</intervention_name>
    <description>Part 2: Patients receiving Orkambi therapy for at least 3 months as their standard of care will receive 0.25 mg BAY63-2521 tid for 14 days, increasing to 0.5 mg, 1 mg and 2 mg for 14 days each.</description>
    <arm_group_label>Arm 4: BAY63-2521</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent available before any study specific tests or procedures are
             performed

          -  Patients must be at least 18 years of age at time of inclusion (i.e. upon signature
             of informed consent)

          -  Patient diagnosed with Cystic Fibrosis according to standard criteria (i.e. either
             elevated sweat chloride content above 60 mmol/ L and/ or genetic testing)

          -  Patient is homozygous for the deltaF508 mutation

          -  Patient has a mild-to-moderate stage of lung disease as determined by FEV1 (FEV1
             between 40 and 100% predicted)

          -  Patient has a stable condition of lung disease (no ongoing or recent pulmonary
             exacerbation and no change in current treatment) within the last 4 weeks prior to
             screening

          -  Ability and willingness to understand and follow study procedures for the entire
             study

          -  Patients do not smoke. Patients with a history of smoking can be included, if they
             have refrained from smoking for the last 3 months. If a patients starts smoking
             during the study participation, he/ she needs to be excluded and considered to be a
             drop out

          -  Body mass index (BMI): ≥ 16 kg/ m² (calculated by dividing the patient's weight by
             the square of his/ her height [kg/ m2])

        Inclusion criterion valid for study part 1 only:

        - Women of childbearing potential must agree to use adequate contraception when sexually
        active. 'Adequate contraception' is defined as one highly effective form of contraception
        (intrauterine devices [IUD], contraceptive implants or tubal sterilization) or a
        combination of methods (hormone method with a barrier method ). If a partner's vasectomy
        is the chosen method of contraception or if a partner has documented azoospermia, a
        hormone or barrier method must be used in combination. Adequate contraception is required
        from the signing of the informed consent form up until 4 weeks after the last study drug
        administration

        Inclusion criteria valid for study part 2 only:

          -  Women of childbearing potential must agree to use adequate contraception when
             sexually active. 'Adequate contraception' is defined as one highly effective form of
             contraception (intrauterine devices [IUD], contraceptive implants or tubal
             sterilization) or a combination of methods (hormone method with a barrier method).
             For patients on Orkambi hormonal methods (including hormonal oral contraceptives)
             cannot be accepted in this study. They need to choose non-hormonal methods. If a
             partner's vasectomy is the chosen method of contraception or if a partner has
             documented azoospermia, a hormone or barrier method must be used in combination.
             Adequate contraception is required from the signing of the informed consent form up
             until 4 weeks after the last study drug administration

          -  Patients receiving Orkambi (Lumcaftor + Ivacaftor) as part of their standard care
             need to be on stable Orkambi treatment for at least 3 months prior to screening
             (patients on Lumacaftor and/or Ivacaftor are excluded in part 1)

        Exclusion Criteria:

          -  Patients with Cystic Fibrosis with any background other than homozygous deltaF508
             mutation

          -  Exclusion criterion only valid for study part 1: Patients receiving treatment with
             Lumacaftor and/ or Ivacaftor

          -  Active state of hemoptysis or pulmonary hemorrhage, including those events managed by
             bronchial artery embolization. Also any history of moderate hemoptysis within the 3
             months prior to inclusion

          -  Any history of pneumothorax, bronchial artery embolization or massive hemoptysis.
             Massive hemoptysis being defined as acute bleeding &gt;240 mL in a 24-hour period or
             recurrent bleeding &gt;100 mL/ d over several days

          -  A positive sputum culture for Burkholderia cenocepacia, Burkholderia dolosa, and/ or
             Mycobacterium absessus either currently or within the previous year

          -  Active allergic broncho-pulmonary aspergillosis

          -  Current pulmonary exacerbation

          -  Known history of solid organ transplantation

          -  Known history of any form of pulmonary hypertension

          -  Clinically relevant deviations of the screened laboratory parameters from reference
             ranges outside of expected changes for Cystic Fibrosis patients, especially a
             hemoglobin value below 110 g/L or a creatinine clearance based on the Cockcroft-Gault
             formula &lt; 15 ml/ min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For trial location information (Phone Menu Options '3' or '4')</last_name>
    <phone>(+)1-888-84 22937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-1711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <state>North Ireland</state>
        <zip>BT12 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>June 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>delta F508</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Sweat Chloride</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
